Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
about
Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segmentCetuximab/C225-induced intracellular trafficking of epidermal growth factor receptorClassic and contemporary approaches to modeling biochemical reactionsErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesCombating acquired resistance to tyrosine kinase inhibitors in lung cancerProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerExploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Tumor antigen-specific monoclonal antibodies and induction of T-cell immunityThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerMolecular mechanisms of disease-causing missense mutationsDeveloping irreversible inhibitors of the protein kinase cysteinomeEnhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancerThe Juxtamembrane Region of the EGF Receptor Functions as an Activation Domainc-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinasesActivation of tyrosine kinases by mutation of the gatekeeper threonineNovel mutant-selective EGFR kinase inhibitors against EGFR T790MStructural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 ProteinErlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domainStructural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptorStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainMechanism for activation of mutated epidermal growth factor receptors in lung cancerStructural and Functional Analysis of G Protein-Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed AnalogStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerMechanisms of drug resistance in kinases.A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerNew developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceConstitutive activation of epidermal growth factor receptor promotes tumorigenesis of Cr(VI)-transformed cells through decreased reactive oxygen species and apoptosis resistance developmentIdentification of potent EGFR inhibitors from TCM Database@TaiwanLapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffoldsMultiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationQSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFRContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsGefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF
P2860
Q24309071-BE2399DE-5985-4EE0-8524-887D2974E623Q24314620-2CEBD607-4EB1-436E-BB4D-6262F11481DFQ24619013-4238F3D8-C15E-4180-AEFD-BE0D9F4CC4E6Q24621754-CE666510-5BDF-45AB-9D51-6D2643D879F4Q24649549-B69C590F-882D-48B4-ACF5-AD427F32F858Q26741998-FF717E7F-E224-45CE-B789-92918F0E9F1FQ26797297-7DB415F8-75EB-44FA-845E-1CEDCFA1C9A0Q26824877-B66003D0-0C3F-4AB3-83D7-DEA42F27C64DQ26852215-8B113230-9D39-4FE5-98F8-5075C5AA6E46Q27001584-224EE457-2886-42E9-BC3B-C2C69763CEA7Q27009908-02F273CF-7131-4299-B7F8-012EE788C96AQ27021738-3932DFCE-8616-4CA5-A925-57472D156D60Q27021940-56F8203D-32E6-4A14-AD62-79E58749F661Q27027983-B255B657-BB71-4D47-8E49-CF8D92C9AD27Q27305848-5E0CA4F5-B897-4804-9EA9-D1133C816257Q27646344-C7B6E997-1ECE-430C-A708-9673B68693A5Q27649203-4032224E-F086-4AF9-953F-1A9B77566328Q27649889-72860D33-2193-41E1-A934-0BEEFDD737EEQ27652166-0250DEDD-67B6-4942-B195-E11C20439B9DQ27658766-2537A2EB-0252-4EF6-9306-12EB731C310CQ27667382-22D8B738-74B8-4290-9AE6-44040AAD69F4Q27674725-6F38BF52-A0E9-4DC2-8B32-913DED111F8AQ27677383-D76268D8-D5C6-4873-81C7-30DB4C7A193AQ27678454-9848EE57-2090-425D-BA1B-D70D913916C4Q27679902-203C71AE-73AD-4235-97B9-4B6FC46A3D3FQ27680587-7B4C92D3-4AFD-44B8-B4FD-44EDFD156086Q27680966-FCFDAF6A-B9E8-4728-96A7-DD2E4F99D27CQ27692567-D3685AE4-FBE0-4B67-B5B3-D4C1F2F194EBQ27852979-40F9B5EA-FE60-48ED-B6B2-720DE74F4C37Q27853236-0FDAB54C-F737-4016-9885-97136EBBC933Q28075511-5A2B2003-FB1F-45E1-AB3B-7A65296BB03BQ28079320-B2796101-CCE4-4CD2-9B6F-48F12615CE69Q28386290-F8A57F13-443D-40CD-9FAD-A67EFF4C5F5FQ28477481-5BC8D4CB-CDBC-45B1-95E2-73679567B602Q28486270-0509544B-1F6B-490E-AAF7-1AD17D82E747Q28486282-418EEBF0-CC6C-4249-B333-2B7122BB1EC3Q28534577-94A46111-D3E9-409B-A98E-BE5869BC7FA7Q28540324-6D9F8F23-B743-4156-A930-DAFC56FEF777Q28547357-DE7D5BEE-104A-4C10-8091-53F4F3EF5A8EQ28740473-9E308235-5265-4E24-8E1F-2723FEFEAED3
P2860
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@ast
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@en
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@nl
type
label
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@ast
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@en
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@nl
altLabel
Structures of lung cancer-deri ...... erential inhibitor sensitivity
@en
prefLabel
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@ast
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@en
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@nl
P2093
P2860
P3181
P1433
P1476
Structures of Lung Cancer-Deri ...... erential Inhibitor Sensitivity
@en
P2093
Cai-Hong Yun
Michael J Eck
Michele S Woo
Titus J Boggon
P2860
P304
P356
10.1016/J.CCR.2006.12.017
P407
P577
2007-03-01T00:00:00Z